Comparative Pharmacology
Head-to-head clinical analysis: AMOXIL versus AUGMENTIN 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXIL versus AUGMENTIN 250.
AMOXIL vs AUGMENTIN '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes, leading to bacterial lysis.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to beta-lactamases, preventing hydrolysis of amoxicillin.
250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours; for severe infections, up to 500 mg every 8 hours or 875 mg every 12 hours.
One 250 mg amoxicillin/125 mg clavulanate tablet orally every 8 hours for 7-10 days.
None Documented
None Documented
Terminal half-life: 1-1.5 hours (normal renal function); prolonged to 7-20 hours in anuria; neonates: 3-4 hours.
Amoxicillin: 1.0-1.3 hours; clavulanate: 1.0-1.5 hours; prolonged in renal impairment (up to 7 hours for amoxicillin in anuria).
Renal: 60-80% unchanged via tubular secretion and glomerular filtration; Biliary/fecal: minor, <5% excreted in bile; dose adjustment in CrCl <30 mL/min.
Renal: ~50-70% as amoxicillin, ~25-40% as clavulanate unchanged; biliary/fecal: minor (10-15% combined).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic